Amer Zeidan, Chief of the Division of Hematologic Malignancies and Professor of Medicine at Yale University, shared a post on X:
“Long awaited results of VERONA (PH3 of aza-ven vs aza) in higher risk MDS press release with negative top line results for OS. We unfortunately remain in the dreaded boulevard of broken dreams in higher risk MDS. Subgroup analyses will be important.”
More posts featuring Amer Zeidan on OncoDaily.